Redeye updates its estimates and valuation following Freemelt’s Q2 report, which came in below our e...
Scanfil's Q2 net sales and clean EBIT were slightly below LSEG Data & Analytics consensus.
Q2 EBITDA 8% above on lower costs Reduced guidance, yet only small changes to estimates Reiterate fa...
Redeye is positive to the news of FiiZK divesting its lice skirt business FiiZK Protection AS.
Redeye provides a research update following the Q2 2024 report from Respiratorius.
Q2 production slightly below Focus in Q2: Exploration, FDP on Block 56 & strategic review P/NAV of 0...
Redeye comments on Freemelt’s Q2 results, which came in lower than expected because some anticipated...
DT’s Q2 results clearly topped estimates as SBU and IBU grew a lot faster than expected, while MBU s...
NoHo Partners reported Q2 EBIT of EUR 9.7m (-9% y/y), 17% below Vara Research consensus and 20% belo...
We expect positive group revenue growth in Q2 after a decline for the last four quarters on a y/y ba...
Solteq published preliminary Q2 figures, showing better profitability than we had estimated, while t...
We maintain our estimates intact ahead of Suominen’s Q2 report, due on 9 August.
Redeye notes a weak Q2 for Sedana Medical, with lower sales and higher costs than we expected.
The beginning of 2024 was tough, but the worst could be behind us.
Redeye sees Q2 sales in line with our forecast but higher costs, prompting us to lower our 2024e EBI...
